Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
July 2019
-
Media ReleaseNovartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trialsIn MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant improvement in overall survival in post-menopausal women in first- and second-line setting Kisqali is the only CDK4/6…
-
Q&A with new NIBR CIO Dimitris Agrafiotis
The Chief Information Officer of the Novartis Institutes for BioMedical Research discusses his new role.
-
Key ReleaseNovartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will…
-
Media ReleaseNovartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindnessLucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark…
-
Hardwiring the future
A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.
-
Media ReleaseAveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)The FDA's May 2019 approval of Zolgensma ®, a gene therapy for spinal muscular atrophy (SMA) in pediatric patients less than 2 years of age, marked an important milestone within the SMA community.…
-
Flexibility at Novartis: Linda Karpiak
Karpiak explains how her flexible schedule enables her to succeed at work while staying active in her community.
-
Media ReleaseSandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosisIntegrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] Osteoporosis accounts for 8.9m bone fractures…
-
Media ReleaseNovartis key multiple sclerosis product Gilenya® approved in ChinaChinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older. Multiple sclerosis (MS) is…
-
Featured NewsNovartis Financial Results – Q2 2019
Novartis announced the company’s financial results for the second quarter and first half of 2019.
-
Media ReleaseNovartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increasedContinuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +…
-
Media ReleaseNovartis au 2e trimestre: fortes ventes, croissance à deux chiffres du résultat opérationnel core et lancements de Zolgensma et de Piqray; prévision des ventes et du résultat revue à la hausseChiffre d'affaires net des activités poursuivies[1] en hausse de 8% (tcc[2], +4% USD) soutenu par: Cosentyx: USD 858 millions, +25% (tcc) stimulé principalement par le maintien de la forte…
Pagination
- ‹ Previous page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- …
- 150
- › Next page